Cocrystal Pharma Inc. Announces Phase 1 Study Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Cocrystal Pharma Inc. announced positive Phase 1 study results for its pan-viral inhibitor CDI-988, presented at the 2025 Military Health System Research Symposium. The randomized, double-blinded, placebo-controlled study showed that all doses (100 mg to 1200 mg) were well tolerated. CDI-988 aims to treat norovirus, addressing a significant medical need. A Phase 1b study with norovirus-infected healthy subjects is planned for later this year. The development is supported by Cocrystal’s structure-based platform technology for broad-spectrum antivirals.
Cocrystal Pharma Inc. has announced positive results from a Phase 1 clinical study of its oral, direct-acting pan-viral inhibitor CDI-988. The study, which was randomized, double-blinded, and placebo-controlled, demonstrated that all doses of CDI-988, ranging from 100 mg to 1200 mg, were well tolerated. These findings were presented at the 2025 Military Health System Research Symposium. CDI-988 is being developed as a potential prophylaxis and treatment for norovirus, addressing a critical unmet medical need due to the lack of approved treatments or vaccines for the virus. Cocrystal Pharma plans to initiate a Phase 1b study with norovirus-infected healthy subjects later this year. The development of CDI-988 is supported by Cocrystal’s proprietary structure-based platform technology, aimed at creating novel broad-spectrum antivirals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022153), on August 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
